CORCEPT THERAPEUTICS INC Marketable Securities, Unrealized Gain (Loss)
CORCEPT THERAPEUTICS INC (CORT) reported Marketable Securities, Unrealized Gain (Loss) of -$482.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2026-07-29
- CORCEPT THERAPEUTICS INC marketable securities, unrealized gain (loss) for the quarter ending 2026-06-30 was -$482.00K, a 130.14% decline year-over-year.
- CORCEPT THERAPEUTICS INC marketable securities, unrealized gain (loss) for the quarter ending 2026-03-31 was -$1.35M, a 248.07% decline year-over-year.
- CORCEPT THERAPEUTICS INC marketable securities, unrealized gain (loss) for the quarter ending 2025-09-30 was $50.00K, a 96.64% decline year-over-year.
- CORCEPT THERAPEUTICS INC marketable securities, unrealized gain (loss) for the quarter ending 2025-06-30 was $1.60M.
- CORCEPT THERAPEUTICS INC marketable securities, unrealized gain (loss) for fiscal 2018 was $5.00K.
- CORCEPT THERAPEUTICS INC marketable securities, unrealized gain (loss) for fiscal 2017 was -$75.00K.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$482.00K 10-Q · filed 2026-07-29 | -$1.83M derived: sum of 2 quarters · filed 2026-07-29 | ||
| 2026-03-31 | -$1.35M 10-Q · filed 2026-07-29 | |||
| 2025-09-30 | $50.00K 10-Q · filed 2025-11-04 | $1.65M derived: sum of 2 quarters · filed 2026-07-29 | $2.56M derived: sum of 3 quarters · filed 2026-07-29 | |
| 2025-06-30 | $1.60M 10-Q · filed 2026-07-29 | $2.51M derived: sum of 2 quarters · filed 2026-07-29 | ||
| 2025-03-31 | $909.00K 10-Q · filed 2026-07-29 | |||
| 2024-09-30 | $1.49M 10-Q · filed 2025-11-04 | $1.31M derived: sum of 2 quarters · filed 2025-11-04 | $962.00K derived: sum of 3 quarters · filed 2025-11-04 | |
| 2024-06-30 | -$174.00K 10-Q · filed 2025-11-04 | -$525.00K derived: sum of 2 quarters · filed 2025-11-04 | ||
| 2024-03-31 | -$351.00K 10-Q · filed 2025-11-04 | |||
| 2023-09-30 | -$279.00K 10-Q · filed 2024-10-30 | -$81.00K derived: sum of 2 quarters · filed 2024-10-30 | $635.00K derived: sum of 3 quarters · filed 2024-10-30 | |
| 2023-06-30 | $198.00K 10-Q · filed 2024-10-30 | $914.00K derived: sum of 2 quarters · filed 2024-10-30 | ||
| 2023-03-31 | $716.00K 10-Q · filed 2024-10-30 | |||
| 2022-09-30 | -$240.00K 10-Q · filed 2023-11-01 | -$1.03M derived: sum of 2 quarters · filed 2023-11-01 | -$2.15M derived: sum of 3 quarters · filed 2023-11-01 | |
| 2022-06-30 | -$790.00K 10-Q · filed 2023-11-01 | -$1.91M derived: sum of 2 quarters · filed 2023-11-01 | ||
| 2022-03-31 | -$1.12M 10-Q · filed 2023-11-01 | |||
| 2021-09-30 | -$100.00K 10-Q · filed 2022-11-03 | -$134.00K derived: sum of 2 quarters · filed 2022-11-03 | -$300.00K derived: sum of 3 quarters · filed 2022-11-03 | |
| 2021-06-30 | -$34.00K 10-Q · filed 2022-11-03 | -$200.00K derived: sum of 2 quarters · filed 2022-11-03 | ||
| 2021-03-31 | -$166.00K 10-Q · filed 2022-11-03 | |||
| 2020-09-30 | -$263.00K 10-Q · filed 2021-11-03 | $267.00K derived: sum of 2 quarters · filed 2021-11-03 | $316.00K derived: sum of 3 quarters · filed 2021-11-03 | |
| 2020-06-30 | $530.00K 10-Q · filed 2021-11-03 | $579.00K derived: sum of 2 quarters · filed 2021-11-03 | ||
| 2020-03-31 | $49.00K 10-Q · filed 2021-11-03 | |||
| 2019-09-30 | -$7.00K 10-Q · filed 2019-11-07 | $220.00K derived: sum of 2 quarters · filed 2019-11-07 | $384.00K derived: sum of 3 quarters · filed 2020-05-04 | |
| 2019-06-30 | $227.00K 10-Q · filed 2019-11-07 | $391.00K derived: sum of 2 quarters · filed 2020-05-04 | ||
| 2019-03-31 | $164.00K 10-Q · filed 2020-05-04 | |||
| 2018-12-31 | $5.00K 10-K · filed 2019-02-26 | |||
| 2018-09-30 | $51.00K 10-Q · filed 2019-11-07 | $75.00K derived: sum of 2 quarters · filed 2019-11-07 | -$2.00K derived: sum of 3 quarters · filed 2019-11-07 | |
| 2018-06-30 | $24.00K 10-Q · filed 2019-11-07 | -$53.00K derived: sum of 2 quarters · filed 2019-11-07 | ||
| 2018-03-31 | -$77.00K 10-Q · filed 2019-11-07 | |||
| 2017-12-31 | -$75.00K 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |